RIGL

Rigel Pharmaceuticals, Inc. - Common Stock (RIGL)

About Rigel Pharmaceuticals, Inc. - Common Stock (RIGL)

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Details

Daily high

$19.80

Daily low

$18.92

Price at open

$19.20

52 Week High

$29.82

52 Week Low

$7.48

Market cap

346.0M

Dividend yield

0.00%

Volume

142,463

Avg. volume

180,705

P/E ratio

9.34

Rigel Pharmaceuticals, Inc. - Common Stock News